Alderic M. Fraslin

Villejuif, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Author Reply.

Author Reply.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: May 06, 2026

Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Cost-Utility Analysis Alongside the GORTEC 2014-01 TPExtreme Trial: TPEx Versus EXTREME as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: February 10, 2025

A microsimulation model based on healthcare pathways to estimate the impact of COVID-19 pandemic-induced delays on breast cancer mortality.

A microsimulation model based on healthcare pathways to estimate the impact of COVID-19 pandemic-induced delays on breast cancer mortality.

Journal: Journal of clinical epidemiology

Published: December 16, 2024

Incidence of Bladder Cancer, Healthcare Pathways, and Economic Burden: A Real-World Observational Study From the French National Healthcare System Database.

Incidence of Bladder Cancer, Healthcare Pathways, and Economic Burden: A Real-World Observational Study From the French National Healthcare System Database.

Journal: Clinical genitourinary cancer

Published: August 22, 2024

Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the coblance cohort.

Characteristics, management and survival outcomes in patients with muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup analysis from the coblance cohort.

Journal: BMC urology

Published: August 12, 2024

Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life.

Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life.

Journal: BMJ open

Published: December 21, 2023

Unresolved questions regarding the promise of the TPEx regimen - Authors' reply.

Unresolved questions regarding the promise of the TPEx regimen - Authors' reply.

Journal: The Lancet. Oncology

Published: May 12, 2021

Impact of COVID-19 on healthcare organisation and cancer outcomes.

Impact of COVID-19 on healthcare organisation and cancer outcomes.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 05, 2021

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 16, 2021

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.

Journal: The Lancet. Oncology

Published: September 25, 2020

Showing 1-10 of 10

Last Updated: 09/26/2026